British Journal of Cancer · 2005 · 44 citations · 34 references
MedicineOncologyGastrointestinal OncologyMolecular OncologySurvival AnalysisBiomarker ValidationCancer BiomarkersCancer Molecular DiagnosticsCancer Survival AnalysisGastric CancerMolecular Tumor ProfilingArea Under The Receiver Operating Characteristic CurveCancer Recurrence RiskPrognostic Biomarker ValidationPrognostic Risk AssessmentPrognostic Rna BiomarkersReceiver Operating Characteristic AnalysisRecurrence Of Gastric CancerRecurrence-free Survival
Prediction of peritoneal relapse is extremely important for gastric cancer patients after curative surgery. The present study prospectively validates the prognostic ability of quantifying carcinoembryonic antigen (CEA) mRNA in peritoneal washes by real-time reverse transcriptase-polymerase chain reaction. Based on a retrospective study of 197 curatively resected gastric cancer patients (training set), we determined a cutoff value of CEA mRNA using receiver-operating characteristic curve. We used this cutoff value to validate the risk of peritoneal recurrence in a new cohort of 86 gastric cancer patients (validation set) between July 2000 and December 2002 in a prospective study. During the median 30 months of postoperative surveillance, 20 of the 86 patients died, and 13 of the 20 developed peritoneal metastases. Peritoneal recurrence-free survival as well as overall survival was significantly worse in patients with positive CEA mRNA (P<0.0001). Multivariate analysis with the Cox proportional hazards model showed that positive CEA mRNA was a significant independent risk factor with both survival (P=0.0130) and peritoneal recurrence-free survival (P=0.0006) as end points. These results indicate that quantitation of CEA mRNA in peritoneal washes is a reliable prognostic indicator of peritoneal recurrence in the clinical setting.
34
Phase II Study of S-1, a Novel Oral Derivative of 5-Fluorouracil, in Advanced Gastric Cancer
Wasaburo Koizumi, Minoru Kurihara, Shuji Nakano et al. · Oncology · 2000 · 440 citations
Medicine, Oncology, Pharmacology +15